Heron Therapeutics (HRTX) Revenue (2010 - 2026)

Heron Therapeutics has reported Revenue for 12 years, with the latest figure at $34.7 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 10.78% year-over-year to $34.7 million; the trailing twelve-month figure through Mar 2026 stood at $150.7 million (up 1.48% YoY), and the FY2025 full-year result was $154.9 million, up 7.36% from the prior year.
• Revenue for Q1 2026 stood at $34.7 million, down from $40.6 million in the prior quarter.
• The five-year high for Revenue was $40.8 million in Q4 2024, with the low at $23.5 million in Q1 2022.
• Historically, Revenue has averaged $33.4 million across 5 years, with a median of $34.2 million in 2023.
• Annual changes were most pronounced in 2022 — Revenue surged 45.38% — and 2026, when it fell 10.78%.
• Heron Therapeutics' Revenue stood at $30.0 million in 2022, then rose by 14.0% to $34.2 million in 2023, then rose by 19.13% to $40.8 million in 2024, then fell by 0.47% to $40.6 million in 2025, then retreated by 14.48% to $34.7 million in 2026.
• The last three Revenue figures came in at $34.7 million (Q1 2026), $40.6 million (Q4 2025), and $38.2 million (Q3 2025), per Business Quant data.